Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Pediatric Vaccine Market Expected to Grow Between 2025 And 2029?

The size of the pediatric vaccine market has seen significant growth lately. It is predicted to increase from $44.2 billion in 2024 to $46.95 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.2%. The historical growth is associated with a rise in chronic illnesses, implementation of immunization strategies to eliminate endemic diseases, and heightened financing for vaccine research.

The market size for pediatric vaccines is projected to witness substantial expansion in the coming years, escalating to $62.48 billion by 2029, with a compound annual growth rate (CAGR) of 7.4%. This growth anticipated over the forecast period can be attributed to a rise in the incidence of invasive cervical cancer, a robust pipeline in the later stages, and approvals for new drugs, as well as a growing occurrence of infectious diseases. Significant trends observed during the forecast period encompass the development of combination vaccines to satisfy market needs, investing in research and development for creating effective vaccines, a focus on the production of live attenuated vaccines, the utilization of novel immune engineering and advanced delivery systems, and the application of artificial intelligence (AI) in vaccine development to streamline the process and facilitate easier manufacturing.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2824&type=smp

Which Primay Drivers Are Accelerating Growth in the Pediatric Vaccine Market?

The growth of the pediatric vaccines market is being driven by the escalating occurrence of chronic diseases such as tuberculosis, diphtheria, and pneumonia in individuals aged 15 years and younger. Children and adolescents with chronic conditions are seeing an uptick in danger of serious outcomes and complications from infectious diseases. Around half of the total population (46.6%, or 11.6 million) reported at least one chronic illness, according to data collected and analyzed in March 2022 by the Australian Bureau of Statistics, an independent statutory organization based in Australia responsible for collating and assessing data and making factual recommendations. As the number of children suffering from chronic diseases continues to rise, so does the demand for immunization against such diseases, thereby propelling the expansion of the pediatric vaccine market.

Which Primary Segments of the Pediatric Vaccine Market Are Driving Growth and Industry Transformations?

The pediatric vaccine market covered in this report is segmented –

1) By Vaccine Type: Monovalent, Multivalent

2) By Technology: Live Attenuated, Inactivated, Toxoid, Conjugate, Other Technologies

3) By Application: Infectious Disease, Allergy, Cancer

Subsegments:

1) By Monovalent: Single Antigen Vaccines, Specific Disease Vaccines

2) By Multivalent: Combination Vaccines, Polyvalent Vaccines

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=2824&type=smp

Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Pediatric Vaccine Market?# Market?

North America was the largest region in the pediatric vaccine market in 2024. Middle East is expected to be the largest growing region in the global pediatric vaccine market share during the forecast period. The regions covered in the pediatric vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Which Technological Trends Are Reshaping the Pediatric Vaccine Industry Dynamics?

The need for unique vaccines continues to rise to provide effective protection against daunting infectious diseases such as tuberculosis and HIV/AIDS, as well as non-communicable chronic diseases like cancer and neurodegenerative diseases. Innovations in vaccine development include the design of immunogenic structures, gene-oriented vaccine platforms, and the efficient formulation of recombinant antigen adjuvants. There’s an ongoing effort by pediatric vaccine manufacturers and designers to innovate vaccine design and manufacturing technologies to keep up with the escalating demand for novel vaccines. As an illustration, Pfizer Inc., a pharmaceutical manufacturing firm based in the United States, received U.S. FDA approval for REVNAR 20, a 20-valent Pneumococcal Conjugate Vaccine for youngsters and infants, in April 2023.

View the full report here:

https://www.thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report

What Parameters Are Used to Define the Pediatric Vaccine Market?

Pediatric vaccines refer to medications that are typically given to children as a form of protection against serious, frequently fatal diseases. They get the children’s body ready to battle the disease more quickly and successfully by boosting its natural defenses.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2824

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model